Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)-Reference-Cited by-同舟云学术

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Published:2020-04 Issue:1 Volume:157 Page:161-166
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Santin Alessandro D.^ORCID,Deng Wei,Frumovitz Michael^ORCID,Buza Natalia,Bellone Stefania,Huh Warner,Khleif Samir,Lankes Heather A.,Ratner Elena S.,O'Cearbhaill Roisin E.,Jazaeri Amir A.,Birrer Michael

Funder

National Cancer Institute

National Institutes of Health

Puma

Immunomedics

Gilead

Synthon

Merck

Boehringer Ingelheim

Genentech

Tesaro

AstraZeneca

Stryker

BioLine Therapeutics

Bristol-Myers Squibb

IO Biotechnologies

Lycera

MediImmune

Syndax Pharmaceuticals

KAHR Medical

BMS

Iovance

Aravive

Pfizer

Immatics USA

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference17 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J. Clin.,2018

2. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study;Monk;J. Clin. Oncol.,2009

3. Improved survival with bevacizumab in advanced cervical cancer;Tewari;N. Engl. J. Med.,2014

4. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer;Santin;J. Virol.,1999

5. Vaccination with HPV18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer;Santin;N. Engl. J. Med.,2002

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I);Taiwanese Journal of Obstetrics and Gynecology;2024-09

2. Pharmacotherapy for cervical cancer: current standard of care and new perspectives;Expert Opinion on Pharmacotherapy;2024-08-12

3. Comprehensive Review on Cervical Cancer: Global Health Burden;Current Cancer Therapy Reviews;2024-08-06

4. Trop-2 expression and the tumor immune microenvironment in cervical cancer;Gynecologic Oncology;2024-08

5. GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial;eClinicalMedicine;2024-08